# A Study Evaluating the Efficacy and Safety of De Trastuzumab (T-DXd) in Combination with Immunotherapy for the Neoadjuvant Treatment of HR-positive HER2 Low-expressing Chinese Patients with Early-stage Breast Cancer

> **NCT06733233** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Guangzhou Women and Children's Medical Center** · enrollment: 23 (estimated)

## Conditions studied

- Breast Cancer, Estrogen Receptor-Positive
- HER2 Low Breast Cancer

## Interventions

- **DRUG:** T-DXd combined with immune checkpoint inhibitor

## Key facts

- **NCT ID:** NCT06733233
- **Lead sponsor:** Guangzhou Women and Children's Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-01-01
- **Primary completion:** 2028-01-01
- **Final completion:** 2029-01-01
- **Target enrollment:** 23 (ESTIMATED)
- **Last updated:** 2024-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06733233

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06733233, "A Study Evaluating the Efficacy and Safety of De Trastuzumab (T-DXd) in Combination with Immunotherapy for the Neoadjuvant Treatment of HR-positive HER2 Low-expressing Chinese Patients with Early-stage Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06733233. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*